NOVEL STRATEGIES FOR INTERVENTION OF INFLAMMATORY DISEASES AND CANCER
NOVEL STRATEGIES FOR INTERVENTION OF INFLAMMATORY DISEASES AND CANCER
批准号:
10077119
负责人:
Rongfu Wang
金额:
$31.35万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-07-01 至 2023-05-31
关键词:
AcuteAffectAnimal ModelAntigensAwardBiological ModelsCancer EtiologyCellsCessation of lifeChemicalsColitisColitis associated colorectal cancerColonColorectal CancerColorectal NeoplasmsComplexDevelopmentDiseaseEpithelialEpithelial CellsEpitheliumFundingGene ChipsGeneticGoalsIL6 Signaling PathwayImmuneImmune responseImmune signalingImmune systemInfiltrationInflammationInflammatoryInterleukin-1 betaInterleukin-17Interleukin-6InterventionIntestinesLamina PropriaLymphoid CellMAP3K7 geneMalignant - descriptorMalignant NeoplasmsMediatingMicrobeModelingMolecularMusMyelogenousPathway interactionsPhenotypePlayPreventionPrevention approachProcessResearchResistanceRoleSeptic ShockSerumShapesSignal PathwaySignal TransductionTNF geneTestingTherapeutic InterventionTissuesTumor ImmunityTumor-infiltrating immune cellsUlcerative ColitisUnited StatesWorkbasecell typechemokinecytokineeffective therapygut microbesgut microbiotaimprovedinterleukin-22microbiotamicroorganismneoplastic cellneutrophilnew therapeutic targetnovelnovel strategiespreventresponsetraffickingtumortumor initiationtumor progressiontumorigenesis
中文摘要
项目总结
结直肠癌(CRC)是美国第三大癌症死亡原因,是一种具有挑战性的疾病
涉及免疫细胞、细胞因子介导的途径和肠道微生物区系之间的复杂相互作用-导致
炎症、上皮组织屏障破坏、急性结肠炎和结直肠癌的发展。因此,机械论
迫切需要研究以澄清这些关键变量的相互作用和后果,使
确定治疗干预的新靶点。在我们之前的奖项资助的研究过程中
(R01CA101795)中,我们发现Tak1(转化生长因子-β激活的蛋白激酶1)是一种负向调节因子,即核因子-κB信号转导通路。
在中性粒细胞中发现其在髓系(Tak1ΔM/ΔM)中的特异性缺失导致增加
促炎细胞因子(IL-1β、IL-6和肿瘤坏死因子-α)和对内毒素诱导的感染性休克的更高敏感性。
出乎意料的是,Tak1ΔM/ΔM小鼠对化学诱导的急性结肠炎和结直肠癌完全耐受
发展。这种表型与Th17和ILC3细胞在肠道中的显著聚集有关。
固有层和肠道微生物区系组成的变化。进一步的研究显示出显著的抑制
结肠上皮细胞中趋化因子的表达和免疫细胞向结肠组织的运输。这些耐人寻味
新的发现导致我们假设特定的肠道微生物区系,Th17和ILC3细胞及其细胞因子(IL-17
和IL-22)在调节对结肠炎和炎症相关结直肠癌的抵抗力方面发挥关键作用
结肠上皮细胞抑制趋化因子的表达。这一假说的关键预测将得到检验。
在三个具体的研究目标中,都依赖于Tak1ΔM/ΔM模型抑制结肠炎和结直肠癌的发生。
目标1旨在鉴定有助于Th17和ILC3细胞积聚的特定微生物群
从而抵抗实验性结肠炎和结直肠癌。目标2将定义Th17和ILC3细胞的功能
(及其细胞因子)在促进对化学诱导的结肠炎和结直肠癌的抵抗力方面,而目标3将测试
假设Th17/ILC3来源的细胞因子抑制结肠上皮细胞趋化因子的表达,因此
阻断随后免疫细胞对上皮层的渗透,最终诱导癌变
冒号的变化。
在成功完成这项工作后,我们预计将对
推动溃疡性结肠炎和结直肠癌发展的炎症过程,因此具有潜在的
这一网络中的漏洞可能成为预防或治疗这些疾病的目标。
英文摘要
PROJECT SUMMARY
Colorectal cancer (CRC), the third leading cause of cancer deaths in the United States, is a challenging disease
involving complex interplay among immune cells, cytokine-mediated pathways and gut microbiota – leading to
inflammation, disruption of the epithelial tissue barrier, acute colitis and CRC development. Thus, mechanistic
studies are urgently needed to clarify the interactions and consequences of these key variables, enabling the
identification of novel targets for therapeutic intervention. In the course of studies funded by our previous award
(R01 CA101795), we identified TAK1 (TGF-beta-activated kinase 1) as a negative regulator of NF-κB signaling
in neutrophils and found that its specific deletion in the myeloid lineage (Tak1ΔM/ΔM) leads to increased
proinflammatory cytokines (IL-1β, IL-6, and TNF-α) and greater sensitivity to LPS-induced septic shock.
Unexpectedly, Tak1ΔM/ΔM mice were completely resistant to chemically induced acute colitis and CRC
development. This phenotype was associated with a marked accumulation of Th17 and ILC3 cells in the intestinal
lamina propria and alterations of the gut microbiota composition. Further studies showed significant suppression
of chemokine expression in colon epithelial cells and of immune cell trafficking into colon tissues. These intriguing
new findings led us to hypothesize that specific gut microbiota, Th17 and ILC3 cells and their cytokines (IL-17
and IL-22) play critical roles in regulating resistance to colitis and inflammation-related CRC through the
suppression of chemokine expression by colon epithelial cells. Key predictions of this hypothesis will be tested
in three specific research aims, all relying on the Tak1ΔM/ΔM model of suppressed colitis and CRC tumorigenesis.
Aim 1 seeks to identify specific strains of microbiota that contribute to the accumulation of Th17 and ILC3 cells
and thus to resistance to experimental colitis and CRC. Aim 2 will define the functions of Th17 and ILC3 cells
(and of their cytokines) in promoting resistance to chemically induced colitis and CRC, while Aim 3 will test the
hypothesis that Th17/ILC3-derived cytokines inhibit the expression of chemokines by colon epithelial cells, thus
blocking subsequent immune cell infiltration of the epithelial layer and ultimately the induction of malignant
changes in the colon.
Upon successful completion of this work, we expect to have a much-improved understanding of the
inflammatory processes that drive the development of ulcerative colitis and CRC, and thus of potential
vulnerabilities in this network that could be targeted for the prevention or treatment of these disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CD4+ T cells and neoantigens in melanoma immunotherapy.
-
批准号:10532696
-
项目类别:
-
资助金额:$62.75万
-
财政年份:2020
-
负责人:Rongfu Wang
-
依托单位:
CD4+ T cells and neoantigens in melanoma immunotherapy.
-
批准号:10310521
-
项目类别:
-
资助金额:$62.75万
-
财政年份:2020
-
负责人:Rongfu Wang
-
依托单位:
Transport of Effector T cells and Nano-DC vaccine in Breast Cancer
-
批准号:10227174
-
项目类别:
-
资助金额:$16.15万
-
财政年份:2016
-
负责人:Rongfu Wang
-
依托单位:
Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell
-
批准号:7653641
-
项目类别:
-
资助金额:$25.85万
-
财政年份:2006
-
负责人:Rongfu Wang
-
依托单位:
Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell
-
批准号:7275432
-
项目类别:
-
资助金额:$25.85万
-
财政年份:2006
-
负责人:Rongfu Wang
-
依托单位:
Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell
-
批准号:7884621
-
项目类别:
-
资助金额:$13.73万
-
财政年份:2006
-
负责人:Rongfu Wang
-
依托单位:
Reversal of regulatory T cell function in prostate cancer
-
批准号:7087614
-
项目类别:
-
资助金额:$26.63万
-
财政年份:2006
-
负责人:Rongfu Wang
-
依托单位:
Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell
-
批准号:7090947
-
项目类别:
-
资助金额:$26.63万
-
财政年份:2006
-
负责人:Rongfu Wang
-
依托单位:
Reversal of regulatory T cell function in prostate cancer
-
批准号:7658065
-
项目类别:
-
资助金额:$25.85万
-
财政年份:2006
-
负责人:Rongfu Wang
-
依托单位:
Reversal of regulatory T cell function in prostate cancer
-
批准号:8418362
-
项目类别:
-
资助金额:$11.45万
-
财政年份:2006
-
负责人:Rongfu Wang
-
依托单位:
Reversal of regulatory T cell function in prostate cancer
-
批准号:7475675
-
项目类别:
-
资助金额:$25.85万
-
财政年份:2006
-
负责人:Rongfu Wang
-
依托单位:
Reversal of regulatory T cell function in prostate cancer
-
批准号:7903298
-
项目类别:
-
资助金额:$14.81万
-
财政年份:2006
-
负责人:Rongfu Wang
-
依托单位:
Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell
-
批准号:7478088
-
项目类别:
-
资助金额:$25.85万
-
财政年份:2006
-
负责人:Rongfu Wang
-
依托单位:
Reversal of regulatory T cell function in prostate cancer
-
批准号:7272830
-
项目类别:
-
资助金额:$25.85万
-
财政年份:2006
-
负责人:Rongfu Wang
-
依托单位:
Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell
-
批准号:8402769
-
项目类别:
-
资助金额:$12.57万
-
财政年份:2006
-
负责人:Rongfu Wang
-
依托单位:
Novel Strategies for Immunotherapy of Cancer
-
批准号:8332785
-
项目类别:
-
资助金额:$27.2万
-
财政年份:2004
-
负责人:Rongfu Wang
-
依托单位:
Novel Strategies for Immunotherapy of Cancer
-
批准号:8106036
-
项目类别:
-
资助金额:$27.2万
-
财政年份:2004
-
负责人:Rongfu Wang
-
依托单位:
Novel Strategies for Immunotherapy of Cancer
-
批准号:8731181
-
项目类别:
-
资助金额:$26.39万
-
财政年份:2004
-
负责人:Rongfu Wang
-
依托单位:
Novel Strategies for Immunotherapy of Cancer
-
批准号:6819332
-
项目类别:
-
资助金额:$27.77万
-
财政年份:2004
-
负责人:Rongfu Wang
-
依托单位:
Novel Strategies for Immunotherapy of Cancer
-
批准号:8519948
-
项目类别:
-
资助金额:$25.57万
-
财政年份:2004
-
负责人:Rongfu Wang
-
依托单位:
海外基金